Alpha Cognition Inc
NASDAQ:ACOG
Gross Margin
Alpha Cognition Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | Company | Market Cap |
Gross Margin |
||
---|---|---|---|---|---|
CA |
A
|
Alpha Cognition Inc
XTSX:ACOG
|
9.9m CAD | N/A | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
332.9B USD |
71%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
156.1B USD |
64%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
138.8B USD |
78%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.9B USD |
86%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
117.6B AUD |
52%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
52.6B USD |
87%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
75%
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
39.9B USD |
86%
|
Alpha Cognition Inc
Glance View
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-09-19. The Company’s therapeutic pipeline includes ALPHA-1062 and ALPHA-0602. The Company’s ALPHA-1062 development program is primarily focused on clinical and regulatory development, chemistry, manufacturing and control development, and commercial readiness. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein, and is in preclinical development for the treatment of amyotrophic lateral sclerosis. The company has three development programs: ALPHA-1062 in combination with memantine for the treatment of moderate-to-severe Alzheimer’s; ALPHA-1062 nasal formulation for the treatment of mild traumatic brain injury, and ALPHA-0602, for the treatment of amyotrophic lateral sclerosis. ALPHA-1062 is also being researched as a treatment for mild-traumatic brain injury.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Alpha Cognition Inc's most recent financial statements, the company has Gross Margin of 0%.